Perfluorocarbon Liquid: Its Application in Vitreoretinal Surgery and Related Ocular Inflammation

Qi Yu, Kun Liu, Li Su, Xin Xia, and Xun Xu

1 Department of Ophthalmology, Shanghai First People’s Hospital Affiliated to Shanghai Jiaotong University, No. 100 Haining Road, Shanghai 200080, China
2 Shanghai Key Laboratory of Fundus Diseases, Shanghai 200080, China

Correspondence should be addressed to Xun Xu; drxuxun@tom.com

Received 25 January 2014; Accepted 21 February 2014; Published 30 March 2014

Academic Editor: Mario R. Romano

Copyright © 2014 Qi Yu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The application of perfluorocarbon liquids has been well acclaimed in vitreoretinal surgery. Its unique physical properties make it an ideal intraoperative tool to improve the efficiency and safety of surgical procedures in complicated cases. The main functions of perfluorocarbon liquids in vitreoretinal surgery include relocating and fixing the detached retina, displacing the subretinal and subchoroidal to fluid anteriorly, revealing proliferative vitreous retinopathy (PVR) for further maneuvers, protecting the macula from exposure to chemicals with potential toxicity, and assisting the removal of foreign body. The related clinical applications include retinal detachment with severe proliferative vitreoretinopathy, giant tear, diabetic retinopathy (DR), retinopathy of prematurity (ROP), and posterior dislocated crystalline and intraocular lenses. The application of perfluorocarbon liquids has been expedited over the past fewer years. Several PFCLs related ocular inflammations have been observed in in vitro studies, animal studies, and clinical follow-up. The complete removal of PFCLs is recommended at the end of the surgery in most cases.

1. What Are Perfluorocarbon Liquids?

Perfluorocarbon liquids (PFCLs) are a serial of fluorochemicals in which all the hydrogen atoms are replaced by fluorine [1].

PFCLs are not found in nature. Those compounds are industrially produced by methods such as electrochemical fluorination, oligomerization, and telomerization [2]. Characteristically PFCLs have high specific gravity ranging from 1.76 to 2.03, low surface tension, and optical clarity and transparency make them ideal intraoperative tools for vitreoretinal surgery [7]. The gravity of the above-mentioned PFCLs ranges from 1.76 to 2.30, which empowers the liquid to flat the detached retina and displace the underneath fluids anteriorly [8]. The transparency of PLFCs as a colourless and clear media also ensures that the intraoperative usage of the fluid does not affect the observation of the operators during the surgery and intraoperative photocoagulation. The surface tension of PFCLs ensures the liquid staying relatively cohesive after been injected into the vitreous cavity [9, 10]. The low viscosity makes PFCLs easier to handle while injection and removal [11].

2. Commonly Used Types of Perfluorocarbon Liquids and Their Characteristics

Several kinds of perfluorocarbon liquids have been applied in ophthalmology in different countries. They are perfluorooctane (PFO), perfluoroperoxyphenanthrene (Vitreon), perfluorodecalin (PFD), perfluorotributylamide (PFTB) and perfluoroocytlobromide (PFOB), and so forth [5, 6].

The physical properties of PFCLs including high specific gravity, moderate surface tension, low viscosity, and optical clarity and transparency make them ideal intraoperative tools for vitreoretinal surgery [7].

The potential application of PFCLs in medicine was discovered by Clark Jr. and Gollan in 1966. Mammals including mice and cats in the containers filled with fluorocarbon managed
to survive after weeks [12]. With further investigation, PFCLs’ capacity to carry oxygen was confirmed and later developed as blood substitute [13]. In 1982, Haidt et al. used PFCLs as vitreous tamponade in experiments [14]. Zimmerman and Faris used PFCLs as intraoperative tool to relocate the detached retina in 1982 [15]. In 1987, after in vivo and vitro studies of the efficiency and safety of intraoperative application, Chang et al. use PFCLs in vitreous surgeries of retinal detachment patients with severe PVRs [16].

4. The Functions and Related Indications in Vitreoretinal Surgery

4.1. Relocating and Stabilizing the Detached Retina for Further Maneuvers. The gravity of PFCLs in use is about 2 times greater than perfusion solution. So while injected into the vitreous cavity during vitrectomy, the gravity of PFCLs generates a force against the interface downwards. While it is against the detached retina, the injected PFCLs relocate and immobilize the detached posterior retina. And, while PFCLs are gradually injected into the vitreous cavity, the subretinal fluid is pushed anteriorly and thus into the vitreous cavity through the retinal breaks, which often results in avoiding retinotomy for posterior drainage [17]. In some cases, this process can provide information about the location of the unidentified peripheral breaks if subretinal fluid drainage is observed through breaks other than the identified retinal breaks.

4.1.1. Retinal Detachment with Severe PVR. The very first application of PFCLs in vitreoretinal surgery was in patients of retinal detachment with severe PVR [18]. The application of PFCLs has changed surgical management of PVR. Before that, anterior PVR dissection was performed first and then followed by dissection of posterior PVR. The use of PFC eyes with retinal detachments complicated by PVR permits initial dissection of posterior PVR. The injection of PFCLs after initial dissection aids in opening the funnel to provide better visualization of proliferative membranes and a more thorough removal of the membranes [19].

Regarding the retinal reproliferation after surgery, Greve et al. reported that the intraoperative use of PFCLs in vitreoretinal surgery does not prevent postoperative surgery reproliferation, but it does reduce the severity since the application of PFCLs allows for a more complete removal of the epiretinal membranes. Several other studies have demonstrated the usefulness of PFCLs as an intraoperative tool, diagnostically and therapeutically as well in patients with retinal detachment and PVR [20].

4.1.2. Giant Tears. Retinal detachment with giant tears has been a challenging field in vitreoretinal surgery. The mobility of the detached retina is relatively higher and more difficult to be manipulated due to the size and location of the retinal tears. The application of perfluorocarbon liquids stabilizes the detached retina during vitrectomy and displaces the subretinal fluid [21]. Vitreous and perfluorocarbons were well studied for clinical use [22, 23].

Zhioua et al. evaluated the usefulness of an intraoperative injection of PFCLs in 17 eyes with giant retinal tears (between 90 and 220 degrees) associated with grade 3 PVR. They found an improvement in both anatomical and functional prognoses [24].

In the perfluorooctane study group’s work in 2002, Scott and colleagues included 212 eyes of 212 patients with giant tears and followed a median of 3.5 months. 59% percent of the postoperative visual acuity was improved, 24% remained stable, and 16% was worsened. At 6 months, the retina reattachment rate was 76% [25].

With the intraoperative use of PFCLs, giant tears with no severe PVR, the chance of preserving the lens during surgery has been increased. In some cases, no tamponade of silicon oil is needed [26, 27].

4.1.3. Diabetic Retinopathy. Application of PFCL during vitreous surgery for proliferative diabetic retinopathy (PDR) has been reported by several authors, mostly in quite severe cases. The functions of PFCLs during surgery are similar to cases of retinal detachment with severe PVR. PFCL is a useful adjunct during vitrectomy for severe PDR, especially to flatten shrunken retina. PFCL is also efficient to flatten retinal detachments that appeared when relieving tight vitreoretinal adhesion [28]. The application of PFCL also provides a better condition to perform panretinal photocoagulation if needed with lower energy.

In the study of Imamura and his colleagues, the surgical results were acceptable although the follow-up time was relatively short. PFCL was used in the most complicated cases among PDR patients. In those 18 cases, they all showed macular tractional detachment; two had combined rhegmatogenous retinal detachment and one had PVR due to a previous failed vitrectomy for PDR. The anatomical success rate was 89%, and a visual improvement was found in 10 eyes (55%) [29].

4.1.4. Retinopathy of Prematurity and Other Complex Pediatric Retinal Detachment. Perfluorooctane has been used in complex pediatric retinal detachment with severe PVR. While the posterior proliferative changes were in the inferior retina and gas or silicone was considered less effective or ineffective, perfluorooctane can be considered as a temporary postoperative tamponade [30, 31].

4.2. Floating the Foreign Bodies in the Vitreous Body. A confirmed vitreous foreign body often requires surgical removal. For nonmetal foreign bodies with gravity less than PFCLs (1.76–2.03), the injection of PFCLs into the vitreous body before removal can lift the foreign body away from the retina, thus simplifying the procedures of removal and, mostly, improving the safety of the process [32, 33].

4.2.1. Penetrating Trauma with Posterior Foreign Body. For patients with posterior foreign body after penetrating trauma, PFCLs can assist the removal of light foreign bodies. Trauma cases are often complicated by lens injury, retinal detachment, and vitreous and subretinal or choroidal hemorrhage. The application of PFCLs can also help with the management of retinal detachment, hemorrhage, and proliferation [34].
4.2.2. Posterior Dislocated Crystalline and Intraocular Lenses. In cases of posterior dislocated crystalline or intraocular lenses (IOLs), PFCLs can be applied for the same reason for low gravity vitreous foreign bodies. Even when the dropped lens coexists with a retinal detachment, PFCLs are valuable intraoperative tools because they can aid in the removal of fragments from the vitreous cavity without eliciting iatrogenic retinal damage. Similarly, removing a dislocated IOL by injecting PFCL reduces the risk of injuring the retina during the maneuvers required to retrieve an IOL from the posterior vitreous cavity [35, 36].

Jang reported a modified technique of phacoemulsification in dislocated crystalline lenses in a study of 11 eyes [37]. After the vitreous and posterior hyaloid membranes were removed, perfluorocarbon liquid (PFCL) was injected at the posterior pole to fill the vitreous cavity. The dislocated lens floated on the PFCL, and the injection was ceased once the lens had risen to the iris plane. The lens was then removed from the anterior chamber using standard phacoemulsification procedures. During the phacoemulsification, the PFCL provides a support underneath the nucleus, like a trampoline, and even small fragments can be completely removed. The best-corrected visual outcome was reported more than 20/40 in 11 eyes.

4.3. Protecting the Macula. During vitrectomy, for the purpose of treatment or assisting a procedure, biochemically active agents or drugs may be injected into the vitreous cavity to avoid related toxic effects to the macula. Before the injection of the potentially toxic agents, a small amount of PFCLs is injected into the vitreous cavity to form a bubble covering the macula area, thus separating the macula from the potentially toxic agents [38–40].

4.4. Suprachoroidal Hemorrhage. A suprachoroidal hemorrhage is defined as a hemorrhage in the suprachoroidal space. PFCLs may be useful for expressing suprachoroidal hemorrhage from sclerotomies after vitrectomy. When injected directly over the retina, PFCLs create a posterior tamponade effect, unlike air or gas, by pushing the subchoroidal hemorrhage anteriorly and making it exit through the anterior sclerotomies [41, 42].

PFD or PFO has also been successfully used as an endotamponade tool combined with a tissue plasminogen activator for the treatment of subfoveal hemorrhages in cases of exudative age-related macular degeneration ARMD by preventing or reducing the risk of massive subretinal hemorrhages as a possible complication of treating exudative ARMD [43, 44].

5. The Time-Related Ocular Inflammations Caused by PFCLs

5.1. In Vitro Studies and Animal Studies. Previous in vitro studies have evaluated the effects of direct toxicity and damage due to PFO gravity on human retinal pigment epithelium cells and retinal ganglion cells. They found that PFO was toxic to the ARPE-19, a spontaneously arising human RPE cell line after 7 days of exposure, and PFO generated damage through the mechanical force imparted to retinal ganglion cells [45, 46].

The short tamponade of PFCLs has been reported relatively safe by animal studies. Electron-microscopic studies of intravitreal perfluorotributylamine, perfluorodecalin, and perfluorooctane placed in pig eyes for up to 3 hours indicate a lack of retinal changes. Electrophysiological studies and morphological examination using both light and electron microscopy have revealed no evidence of retinal toxicity after perfluorobiphenylene intravitreal placement for periods up to 48 hours [47, 48].

Intraretinal macrophages and foam cells are observed after 1 to 2 weeks intravitreal placement of PFO, PFD, and PFOB [49]. The narrowing of the outer plexiform layer and degenerative thinning of the outer nuclear layer can be observed progressively as the perfluorocarbon liquids remain longer within the eye [50]. Only the inferior retina exhibits these changes, which are believed to result from the mechanical effects of the high specific gravity of PFCLs which exerts prolonged pressure against the retina. These changes may be only species specific, and similar observations have been made of the superior retina of rabbit eyes following silicone oil injection. Small droplets of perfluoroctane (0.1 mL) injected into the rabbit vitreous appear to be well tolerated, eliciting a macrophage response but no retinal alteration at 6 months [51, 52].

The purification and chemical stability of the perfluorocarbon liquids are highly related to PFCLs induced ocular inflammation. During the production of PFCLs, the impurities are often partly fluorinated substances H and double bonds which are biochemical active and result in ocular inflammation and cytotoxicity [53].

Velikay et al. reported the clinical and histological observations of PFD and PFOB both extremely purified and with 5–30% impurities as short time tamponade in a period of 8 weeks. PFD and PFOB which were not purified caused severe inflammation and retinal detachment. Distinct disarrangement of the outer nuclear layer, vacuolization in the inner nuclear layer, and both edema and vacuolization of the ganglion cell layer were observed [54].

5.2. Clinical Observation. PLFCs related ocular inflammation is also observed in clinical settings especially in cases of subretinal PFCLs [55]. Significant pigment epithelial atrophy throughout the area was vacated by subretinal PFCLs [56]. Subretinal PFCL also can cause local functional changes in the sensitivity of the retina, which has been demonstrated by SLO microperimetry.

Young patients are probably at higher risk for developing severe inflammation. Eyes that develop persistent inflammation, secondary membrane formation, or recurrent RD will need reoperation for removal of this material [57–59].

The use of PFO has been reported to be involved in the occurrence of sticky silicone oil. Interactions of PFCL with silicone oil or heavy silicone oil and variations in temperature are responsible for the increase in shear viscosity and opacity of the oil [60]. PFCL interacts with silicone, dissolving small amounts of the oil into solution over time. And the
surface tension of the surrounding aqueous material and/or contamination of silicone oil with PFCL reduced. While the presence of silicone oil remnants on the retina did not cause lasting side effect, forceful attempts at removal can lead to complications [53].

6. Recent Developments in PFCLs

6.1. Perfluorocarbon-Perfused Vitrectomy. One of the recent developed applications of PFCLs in vitrectomy is perfluorocarbon-perfused vitrectomy. This system employs PFCL perfusion instead of balanced salt solutions (BSSs) during vitrectomy [61]. Oxygenated or nonoxygenated PFCL is used in a recycling or a nonrecycling system for this procedure. PFCL-perfused vitrectomy benefits from several properties of PFCLs [62–65]. In cases with severe diabetic retinopathy, oxygenated PFCLs can be an advantage for the circulation compromised retina. The high oxygenated PFCLs also allow the vitreous surgeons to raise the intraocular pressure to a relatively higher level during a hemostatic surgery. The immiscibility of PFCLs with blood and other intraocular fluids also allows for visible vitreous removal. And most of the functions of PFCLs as intraoperative tool are also applicable while being used as perfusate, such as relocating and stabilizing the detached retina for further maneuvers [66].

6.2. Hydrogenated Hydrofluorocarbon Liquids (HFCLs). To improve the intraocular tolerance of PFCLs as vitreous tamponade, modifications have been made to reduce the specific gravity of the liquids [67]. Hydrogenated hydrofluorocarbon liquids (HFCLs) were developed with reduced specific gravity values and increased lipophilic properties. HFCLs, such as F6H6, F6H8, O44, and O62, were developed to substitute for PFCLs as long-term tamponade in vitreoretinal surgery [68–71]. Due to their properties, these compounds have the potential to remove intraocular silicon oil remnants [72, 73].

7. Conclusion

Regarding the unique physical properties of PFCLs, they have been well accepted as intraoperative tools for vitreoretinal surgery. The application of PFCLs has simplified the surgical procedures and improved the safety of the process especially in severe and complicated cases. Continuous efforts will be made to further improve the compatibility and reduce the related toxicity and ocular inflammation.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgment

This work was sponsored by Program no. 81170862 and Program no. 81273424 of the National Natural Science Foundation of China.

References

[1] S. Chang, “Perfluorocarbon liquids in vitreoretinal surgery,” International Ophthalmology Clinics, vol. 32, no. 2, pp. 153–163, 1992.
[2] Organofluorine Chemistry: Principles and Commercial Applications, Springer, 1994.
[3] A. M. Joussen and D. Wong, “The concept of heavy tamponades—chances and limitations,” Graefes Archive for Clinical and Experimental Ophthalmology, vol. 246, no. 9, pp. 1217–1224, 2008.
[4] G. A. Peyman, J. A. Schulman, and B. Sullivan, “Perfluorocarbon liquids in ophthalmology,” Survey of Ophthalmology, vol. 39, no. 5, pp. 375–395, 1995.
[5] M. H. Berrocal and S. Chang, “Perfluorocarbon liquids in vitreous surgery,” Ophthalmology Clinics of North America, vol. 7, pp. 67–76, 1994.
[6] M. Velikay, A. Wedrich, U. Stolba, P. Datlinger, Y. Li, and S. Binder, “Experimental long-term vitreous replacement with purified and nonpurified perfluorodecalin,” American Journal of Ophthalmology, vol. 116, no. 5, pp. 565–570, 1993.
[7] J. W. Sargent and R. J. Seiff, “Properties of perfluorinated liquids,” Federation Proceedings, vol. 29, no. 5, pp. 1699–1703, 1970.
[8] R. J. Sparrow, A. Jayakumar, M. Berrocal, E. Ozment, and S. Chang, “Experimental studies of the combined use of vitreous substitutes of high and low specific gravity,” Retina, vol. 12, no. 2, pp. 134–140, 1992.
[9] I. Georgalas, I. Ladas, I. Tservakis et al., “Perfluorocarbon liquids in vitreoretinal surgery: a review of applications and toxicity,” Cutaneous and Ocular Toxicology, vol. 30, no. 4, pp. 251–262, 2011.
[10] B. Drury and R. D. Bourke, “Short-term intraocular tamponade with perfluorocarbon heavy liquid,” British Journal of Ophthalmology, vol. 95, no. 5, pp. 694–698, 2011.
[11] S. Chang, “Low viscosity liquid fluorochemistry in vitreous surgery,” American Journal of Ophthalmology, vol. 103, no. 1, pp. 38–43, 1987.
[12] L. C. Clark Jr. and E. Gollan, “Survival of mammals breathing organic liquids equilibrated with oxygen at atmospheric pressure,” Science, vol. 152, no. 3703, pp. 1755–1756, 1966.
[13] T. H. Shaffer, M. R. Wolfson, and L. C. Clark Jr., “Liquid ventilation,” Pediatric Pulmonology, vol. 4, no. 2, pp. 102–109, 1992.
[14] S. J. Haidt, L. C. Clark, and J. Ginsberg, “Liquid perfluorocarbon replacement in the eye,” Investigative Ophthalmology & Visual Science, vol. 22, article 233, 1982.
[15] N. J. Zimmerman and D. Faris, “The use of N-perfluorocarbon amines in complicated retinal detachments,” Investigative Ophthalmology & Visual Science, vol. 25, supplement, article 258, 1984.
[16] S. Chang, E. Ozment, and N. J. Zimmerman, “Intraoperative perfluorocarbon liquids in the management of proliferative vitreoretinopathy,” American Journal of Ophthalmology, vol. 106, no. 6, pp. 668–674, 1988.
[17] U. Stolba, S. Binder, M. Velikay, P. Datlinger, and A. Wedrich, “Use of perfluorocarbon liquids in proliferative vitreoretinopathy: results and complications,” British Journal of Ophthalmology, vol. 79, no. 12, pp. 1106–1110, 1995.
[18] B. F. Carroll, G. A. Peyman, N. J. Mehta et al., “Repair of retinal detachment associated with proliferative vitreoretinopathy using perfluoroperhydrophenanthrene (Vitreon),” Canadian Journal of Ophthalmology, vol. 29, no. 2, pp. 66–69, 1994.
[19] G. E. Coll, S. Chang, J. Sun, M. R. Wieland, M. H. Berrocal, and A. Capone Jr., "Perfluorocarbon liquid in the management of retinal detachment with proliferative vitreoretinopathy," *Ophthalmology*, vol. 102, no. 4, pp. 630–639, 1995.

[20] M. D. J. Greve, G. A. Peyman, and C. M. Millsap, "Relaxing retinotomy under perfluorocarbon liquid," *Ophthalmic Surgery and Lasers*, vol. 27, no. 2, pp. 154–155, 1996.

[21] A. Ambresin, T. J. Wolfensberger, and E. H. Bovey, "Management of giant retinal tears with vitreotomy, internal tamponade, and peripheral 360° retinal photoocoagulation," *Retina*, vol. 23, no. 5, pp. 622–628, 2003.

[22] A. Mathis, V. Pagot, C. Gazagne, and F. Malecaze, "Giant retinal tears: Surgical techniques and results using perfluorodecalin and silicone oil tamponade," *Retina*, vol. 12, no. 3, pp. S7–S10, 1992.

[23] S. Chang, H. Lincoff, N. J. Zimmerman, and W. Fuchs, "Giant retinal tears. Surgical techniques and result using perfluorocarbon liquids," *Archives of Ophthalmology*, vol. 107, no. 5, pp. 761–766, 1989.

[24] R. Zhioua, I. Malek, L. Kria, and A. Ouertani, "Retinal detachment associated with giant retinal tear: surgical procedures and results of the perfluorocarbon liquid-silicone oil exchange with scleral buckling," *Journal Francais d'Ophthalmologie*, vol. 28, no. 4, pp. 366–370, 2005.

[25] I. U. Scott, T. G. Murray, H. W. Flynn Jr., W. J. Feuer, and J. C. Schiffman, "Outcomes and complications associated with giant retinal tear management using perfluoro-n-octane," *Ophthalmology*, vol. 109, no. 10, pp. 1828–1833, 2002.

[26] P. J. Kertes, H. Wafapoore, G. A. Peyman, J. Calixto N., and H. Thompson, "The management of giant retinal tears using perfluoroxyhydrophenanthrene: a multicenter case series," *Ophthalmology*, vol. 104, no. 7, pp. 1159–1165, 1997.

[27] X. Xu, X. Zhang, N. Wu, and P. C. P. Ho, "Treatment of early giant retinal tears with domestic perfluorodecalin and perfluoro propane," *Chinese Medical Journal*, vol. 112, no. 3, pp. 211–213, 1999.

[28] W. E. Smiddy and H. W. Flynn Jr., "Vitrectomy in the management of diabetic retinopathy," *Survey of Ophthalmology*, vol. 43, no. 6, pp. 491–507, 1999.

[29] Y. Imamura, M. Minami, M. Ueki, B. Satoh, and T. Ikeda, "Use of perfluorocarbon liquid during vitrectomy for severe proliferative diabetic retinopathy," *British Journal of Ophthalmology*, vol. 87, no. 5, pp. 563–566, 2003.

[30] C. M. Millsp, G. A. Peyman, P. E. Ma, and M. D. J. Greve, "The surgical management of retinopathy of prematurity using a perfluorocarbon liquid," *International Ophthalmology*, vol. 18, no. 2, pp. 97–100, 1994.

[31] A. Imaizumi, S. Kusaka, H. Noguchi et al., "Efficacy of short-term postoperative perfluoro-n-octane tamponade for pediatric complex retinal detachment," *American Journal of Ophthalmology*, vol. 152, no. 2, pp. 384.e2–389.e2, 2014.

[32] S. Chang, V. Repucci, N. J. Zimmerman, M.-H. Heinemann, and D. J. Coleman, "Perfluorocarbon liquids in the management of traumatic retinal detachments," *Ophthalmology*, vol. 96, no. 6, pp. 785–792, 1989.

[33] U. R. Desai, G. A. Peyman, and C. A. Harper III, "Perfluorocarbon liquid in traumatic vitreous hemorrhage and retinal detachment," *Ophthalmic Surgery*, vol. 24, no. 8, pp. 537–541, 1993.

[34] A. Movshovich, M. Berrocal, and S. Chang, "The protective properties of liquid perfluorocarbons in phacofragmentation of dislocated lenses," *Retina*, vol. 14, no. 5, pp. 457–462, 1994.

[35] E. R. A. Millar and D. H. W. Steel, "Small-gauge transconjunctival vitrectomy with phacoemulsification in the pupillary plane of dense retained lens matter on perfluorocarbon liquids after complicated cataract surgery," *Graefes Archive for Clinical and Experimental Ophthalmology*, vol. 251, no. 7, pp. 1757–1762, 2013.

[36] J. Dalma-Weizhaus, V. Franco-Cardenas, and A. Dalma, "A modified technique for extracting a dislocated lens with perfluorocarbon liquids and viscoelastics," *Ophthalmic Surgery Lasers and Imaging*, vol. 41, no. 5, pp. 572–574, 2010.

[37] H. D. Jang, S. J. Lee, and J. M. Park, "Phacoemulsification with perfluorocarbon liquid using a 23-gauge transconjunctival sutureless vitrectomy for the management of dislocated crystalline lenses," *Graefes Archive for Clinical and Experimental Ophthalmology*, vol. 251, no. 5, pp. 1267–1272, 2013.

[38] A. Nishimura, K. Kita, Y. Segawa, and Y. Shirao, "Perfluorocarbon liquid assists in stripping the ILM to treat detached retina caused by macular hole," *Ophthalmic Surgery Lasers and Imaging*, vol. 33, no. 1, pp. 77–80, 2002.

[39] S. Rizzo, C. Belting, F. Genovesi-Ebert, A. Vento, and F. Cresti, "Modified technique for safer indocyanine-green-assisted peeling of the internal limiting membrane during vitrectomy for macular hole repair," *Graefes Archive for Clinical and Experimental Ophthalmology*, vol. 244, no. 12, pp. 1615–1619, 2006.

[40] P. D. Brazitikos, S. Androudi, S. A. Dimitrakos, and N. T. Stangos, "Removal of the internal limiting membrane under perfluorocarbon liquid to treat macular-hole-associated retinal detachment," *American Journal of Ophthalmology*, vol. 135, no. 6, pp. 894–896, 2003.

[41] S. C. Lee, I. Lee, H. J. Koh, S. H. Kim, and O. W. Kwon, "Massive suprachoroidal hemorrhage with retinal and vitreous incarceration; a vitreoretinal surgical approach," *Korean Journal of Ophthalmology*, vol. 14, no. 1, pp. 41–44, 2000.

[42] U. R. Desai, G. A. Peyman, C. J. Chen et al., "Use of perfluorooxyhydrophenanthrene in the management of suprachoroidal hemorrhages," *Ophthalmology*, vol. 99, no. 10, pp. 1542–1547, 1992.

[43] M. Kamei, Y. Tano, T. Maeno, Y. Ikuno, H. Mitsu, and T. Yusa, "Surgical removal of submacular hemorrhage using tissue plasminogen activator and perfluorocarbon liquid," *American Journal of Ophthalmology*, vol. 121, no. 3, pp. 267–275, 1996.

[44] J. B. Jonas and M. Jäger, "Perfluorohexylcyclooctane endotamponade for treatment of subfoveal hemorrhage," *European Journal of Ophthalmology*, vol. 12, no. 6, pp. 534–536, 2002.

[45] M. Inoue, A. Iriyama, K. Kadonosono, Y. Tamaki, and Y. Yanagi, "Effects of perfluorocarbon liquids and silicone oil on human retinal pigment epithelial cells and retinal ganglion cells," *Retina*, vol. 29, no. 5, pp. 677–681, 2009.

[46] J. Osterholz, M. Winter, J. Winkler et al., "Retinal damage by perfluorocarbon liquids—a question of specific gravity? Intracocular pressure peaks and shearing forces," *Klinische Monatsblatter für Augenheilkunde*, vol. 226, no. 1, pp. 38–47, 2009.

[47] J. Mackiewicz, K. Maaijwee, C. Lüke et al., "Effect of gravity in long-term vitreous tamponade: in vivo investigation using perfluorocarbon liquids and semi-fluorinated alkanes," *Graefes Archive for Clinical and Experimental Ophthalmology*, vol. 245, no. 5, pp. 665–675, 2007.

[48] S. Chang, J. R. Sparrow, T. Iwamoto, A. Gershbein, R. Ross, and R. Ortiz, "Experimental studies of tolerance to intravitreal perfluoro-n-octane liquid," *Retina*, vol. 11, no. 4, pp. 367–374, 1991.

[49] S. H. Elsing, S. Fekrat, W. R. Green, S. Chang, S. D. Wajer, and J. A. Haller, "Clinicopathologic findings in eyes with retained
perfluoro-n-octane liquid; "Ophthalmology, vol. 108, no. 1, pp. 45–48, 2001.

[50] J. Singh, K. Ramaesh, S. B. Wharton, G. Cormack, and H. B. Chawla, "Perfluorodecalin-induced intravitreal inflammation," *Retina*, vol. 21, no. 3, pp. 247–251, 2001.

[51] J. R. Sparrow, R. Ortiz, P. R. MacLeish, and S. Chang, "Fibroblast behavior at aqueous interfaces with perfluorocarbon, silicone, and fluorosilicone liquids," *Investigative Ophthalmology and Visual Science*, vol. 31, no. 4, pp. 638–646, 1990.

[52] D. Zeana, J. Becker, R. Kuckelkorn, and B. Kirchhof, "Perfluorohexyloctane as a long-term vitreous tamponade in the experimental animal," *International Ophthalmology*, vol. 23, no. 1, pp. 17–24, 1999.

[53] M. A. Veckeneer, S. Voogd, E. W. Lindstedt, D. H. Menz, and J. C. Meurs, "An epidemic of sticky silicone oil at the Rotterdam Eye Hospital. Patient review and chemical analyses," *Graefes Archive for Clinical and Experimental Ophthalmology*, vol. 246, no. 6, pp. 917–922, 2008.

[54] M. Velikay, U. Stolba, A. Wedrich, Y. Li, P. Datlinger, and S. Binder, "The effect of chemical stability and purification of perfluorocarbon liquids in experimental extended-term vitreous substitution," *Graefes Archive for Clinical and Experimental Ophthalmology*, vol. 233, no. 1, pp. 26–30, 1995.

[55] G. Lesnoli, T. Rossi, and A. Gelso, "Subfoveal liquid perfluorocarbon," *Retina*, vol. 24, no. 1, pp. 172–176, 2004.

[56] E. Garcia-Valenzuela, Y. Ito, and G. W. Abrams, "Risk factors for retention of subretinal perfluorocarbon liquid in vitreoretinal surgery," *Retina*, vol. 24, no. 5, pp. 746–752, 2004.

[57] S. Y. Cohen, L. Dubois, and C. Elmaleh, "Retinal hole as a complication of long-standing subretinal perfluorocarbon liquid," *Retina*, vol. 26, no. 7, pp. 843–844, 2006.

[58] E. Sakurai and Y. Ogura, "Removal of residual subfoveal perfluoro-n-octane liquid," *Graefes Archive for Clinical and Experimental Ophthalmology*, vol. 245, no. 7, pp. 1063–1064, 2007.

[59] L. Berglin, J. Ren, and P. V. Algvere, "Retinal detachement and degeneration in response to subretinal perfluorodecalin in rabbit eyes," *Graefes Archive for Clinical and Experimental Ophthalmology*, vol. 231, no. 4, pp. 233–237, 1993.

[60] M. R. Romano, J. L. Vallejo-Garcia, F. Parmeggiani et al., "Interaction between perfluorocarbon liquid and heavy silicone oil: risk factor for "Sticky Oil" formation," *Current Eye Research*, vol. 37, no. 7, pp. 563–566, 2012.

[61] H. Quiroz-Mercado, G. Garcia-Aguirre, O. Ustáriz-González, J. Martín-Aviá, and S. Martinez-Jardon, "Perfluorocarbon-perfused vitrectomy using a transconjunctival 25-gauge system," *Retina*, vol. 27, no. 7, pp. 926–931, 2007.

[62] H. Quiroz-Mercado, L. Suarez-Tatá, R. Magdalenic et al., "Perfluorocarbon perfused vitrectomy: Animal Studies," *American Journal of Ophthalmology*, vol. 137, no. 2, pp. 287–293, 2004.

[63] H. Quiroz-Mercado, J. Guerrero-Naranjo, R. Agurto-Rivera et al., "Perfluorocarbon-perfused vitrectomy: a new method for vitrectomy—A Safety and Feasibility Study," *Graefes Archive for Clinical and Experimental Ophthalmology*, vol. 243, no. 6, pp. 551–562, 2005.

[64] H. Quiroz-Mercado, J. Rivera-Sempertegui, T. A. MacKy et al., "Performing vitreous biopsy by perfluorocarbon-perfused vitrectomy," *American Journal of Ophthalmology*, vol. 140, no. 6, pp. 1161–1163, 2005.

[65] J. F. Arevalo, "En bloc perfluorodissection in vitreoretinal surgery: a new surgical technique," *Retina*, vol. 28, no. 4, pp. 653–656, 2008.

[66] Z.-Y. Wang, K.-K. Zhao, D.-S. Zhao, and P.-Q. Zhao, "Dissection under perfluorocarbon liquid: a modified vitrectomy technique for diabetic tractional retinal detachment," *Retina*, vol. 32, no. 4, pp. 848–852, 2012.

[67] K. Kobuch, D. H. Menz, H. Hoerauf, J. H. Dresp, and V.-P. Gabel, "New substances for intraocular tamponades: perfluorocarbon liquids, hydrofluorocarbon liquids and hydrofluorocarbon-oligomers in vitreoretinal surgery," *Graefes Archive for Clinical and Experimental Ophthalmology*, vol. 239, no. 9, pp. 635–642, 2001.

[68] M. J. Martinez-Reina, J. M. Ruiz-Moreno, J. A. Montero, and J. Rueda, "Histopathology and ultrastructure of rabbit retina after intravitreal injection of perfluorohexyloctane (F6H8)," *Current Eye Research*, vol. 30, no. 9, pp. 773–779, 2005.

[69] R. Sorcinelli and M. L. Lai, "Unusual complication after temporary use of perfluorohexyloctane (F6H8) in the treatment of complicated retinal detachment," *Retina*, vol. 25, no. 1, pp. 89–90, 2005.

[70] B. Schatz, Y. El-Shabrawi, A. Haas, and G. Langmann, "Adverse side effects with perfluorohexyloctane as a long-term tamponade agent in complicated vitreoretinal surgery," *Retina*, vol. 24, no. 4, pp. 567–573, 2004.

[71] L. Wagenfeld, O. Zeitz, C. Skevas, and G. Richard, "Long-lasting endotamponades in vitreoretinal surgery," *Ophthalmologica*, vol. 224, no. 5, pp. 291–300, 2010.

[72] D. Tognetto, L. Lepori, R. Lapasin et al., "A new heavy internal tamponade agent in vitreoretinal surgery: An in Vitro Study," *Eye*, vol. 22, no. 8, pp. 1082–1088, 2008.

[73] D. Wong, J. C. Van Meurs, T. Stapler et al., "A pilot study on the use of a perfluorohexyloctane/silicone oil solution as a heavier than water internal tamponade agent," *British Journal of Ophthalmology*, vol. 89, no. 6, pp. 662–665, 2005.